Sandra P D'Angelo, MD retweetledi
Moving Immunotherapy Toward Biomarker-Driven Precision Care - Sandra D'Angelo (@sandrapdangelo)
oncodaily.com/voices/sandra-…
#OncoDaily #Oncology #Cancer #Health #Medicine #Immunotherapy #MedX
English
Sandra P D'Angelo, MD
533 posts
Sandra P D'Angelo, MD
@sandrapdangelo
Sarcoma & Merkel cell carcinoma Medical oncologist l Immunotherapy expert l Memorial Sloan Kettering Cancer Center l Tweets are my own
New York, NY Katılım Mayıs 2015
508 Takip Edilen1.6K Takipçiler
This study helps move sarcoma immunotherapy toward biomarker-driven precision care. By integrating circulating immune profiles, tumor microenvironment features, and digital pathology, we identify signals that may help predict who is most likely to benefit from ICB.
Clinical Cancer Research@CCR_AACR
Now online: Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma doi.org/10.1158/1078-0…
English
Sandra P D'Angelo, MD retweetledi
The #statusquo of #immunotherapy was challenged at @myesmo #ESMORareCancer26 during a dedicated session. Kicked off by Prof. #AntoineItaliano outlining 'established' and 'emerging' #biomarkers and #immune profiling, together with on-going projects in this field
English
Palbociclib → retifanlimab in DDLPS shows immune‐related toxicity with sequential dosing, prompting change to concurrent dosing. Prelim single-cell + flow analyses reveal cell-cycle suppression, senescence induction and T/B-cell infiltration. Analysis of final cohort pending.
Cancer Research Communications@CRC_AACR
Recently published: Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated #Liposarcoma, by Evan Rosenbaum et al. doi.org/10.1158/2767-9… @sandrapdangelo @MSKCancerCenter @WeillCornell #Sarcoma #OpenAccess
English
Sandra P D'Angelo, MD retweetledi
#ESMO25: Adding #immunotherapy to radiotherapy improved rates of pathological response in resectable #sarcoma, but #biomarkers and histology-focused trials are needed to further improve outcomes.
Read more #ESMODailyReporter 📌 ow.ly/EnY550XieWa
@sandrapdangelo
English
Sandra P D'Angelo, MD retweetledi
#CTOS2025 is not only about great science, it's also a perfect opportunity for mentorship for trainees and young fellows!
Don't miss the 🌅 Sunrise Mentorship Session on Nov 13, 7.00 am ( breakfast and coffee will be served ☕)!
Check topics and mentors 🧑🏫on the graphic⬇️
English
Sandra P D'Angelo, MD retweetledi
During the session on novel targets and approaches, Sandra D’Angelo, MD (@sandrapdangelo) of @MSKCancerCenter discusses emerging T-cell therapies for sarcoma, highlighting current data, response mechanisms and future directions.
Key Takeaways:
➡️ Afamicel and letecel show promising results in synovial sarcoma and myxoid round cell liposarcoma.
➡️ New adoptive cell approaches and targets, such as TIL and fusion-driven therapies, could shape the next wave of sarcoma treatment.
English
Sandra P D'Angelo, MD retweetledi
After one patient's synovial sarcoma returned, a clinical trial led MSK helped shrink his tumors by 85%. That same #Tcell therapy is now approved by the @US_FDA.
“This success story is just one example of MSK’s innovative approach to researching new treatments,” says MSK's @sandrapdangelo. “There is a concerted effort to make clinical trials faster and more accessible to more patients." Learn more: bit.ly/3IYdP0Y
English
Wonderful colleague and collaborator!
Dr. Patrick Hwu@PatrickHwuMD
#ScienceSaturday ❓Can engineered T-cell therapies offer new hope for patients with advanced soft tissue sarcomas? ➡️ In this pilot study, D’Angelo (@sandrapdangelo) of @MSKCancerCenter et al., with contributions from Dr. Mihaela Druta (@MihaelaDruta) of @MoffittNews, evaluated letetresgene autoleucel (lete-cel), a T-cell receptor therapy targeting NY-ESO-1, in patients with advanced or metastatic myxoid/round cell liposarcoma (MRCLS). ➡️ Patients who received standard-dose lymphodepletion before lete-cel infusion had an overall response rate of 40 percent, with disease control in 80 percent of cases. These results show promising antitumor activity in a disease with few effective treatment options. 🌟 This study supports the potential of T-cell receptor therapies like lete-cel to improve outcomes for patients with aggressive sarcomas and highlights the critical role of collaborative research. 🔗 Read the full study in @JCO_ASCO: ascopubs.org/doi/full/10.12…
English
Sandra P D'Angelo, MD retweetledi
Join sarcoma medical oncologist @sandrapdangelo TODAY for her session on "Development of Afami-Cel–Engineered Cell Therapy for Advanced Synovial" at @ASCO. #ASCO25
🗓️: 5/31 at 8:30am CT
English
Sandra P D'Angelo, MD retweetledi
CTOS President @SilviaStacchia is inviting everyone to join the Annual Meeting in Boca Raton and celebrate 30th Anniversary of the Society!
Get ready and prepare your abstracts!
Especially on the #sarcoma of the year 🌟#chondrosarcoma
#CTOS2025 #CTOSTweeTOS
English
Had a great time visiting Regis today and speaking with students about recent advances in cancer research and my work in sarcoma treatment. Grateful for the warm welcome and thoughtful questions—future scientists in the making! #CancerResearch @RegisHighSchool @MSKCancerCenter
Regis High School@RegisHighSchool
Dr. Sandra D’Angelo P’28, a Memorial Sloan Kettering medical oncologist, visited Regis today to speak with students about recent breakthroughs in cancer research. She also spoke about her role in groundbreaking studies to better treat those who have been diagnosed with sarcoma.
English
Sandra P D'Angelo, MD retweetledi
🎙️Dr. Sandra D’Angelo highlights the IGNYTE-ESO trial, where Lete-cel shows a 42% response rate in synovial sarcoma and MRCLS, advancing sarcoma care
oncodaily.com/url/221840
@sandrapdangelo @amalsargsyan
#Cancer #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology
English
Sandra P D'Angelo, MD retweetledi
Hear @sandrapdangelo of @MSKCancerCenter and @NamBuiMD of @StanfordCancer discuss developing targeted therapies that effectively address the SS18::SSX fusion oncogene and improving early detection methods.
Watch more here: onclive.com/view/addressin…
English
Sandra P D'Angelo, MD retweetledi
Join us in Boulder, CO April 3, 2025 for inaugural Rocky Mountain #Sarcoma Symposium! incredible speakers @sandrapdangelo @JasonSicklick @GorlickRichard @RLRandallMD and Kaled Alektiar - register here: bit.ly/49v1gU5
time for ⛷️ afterwards! @CUCancerCenter
English
Sandra P D'Angelo, MD retweetledi
Thrilled to share our article this Thanksgiving Eve! 🍂 With expansion of HLA-restricted therapies, we show HLA genotyping via NGS is accurate, streamlines cancer care, boosts trial access, and may reduce disparities. Embedding it in routine panels is key!jamanetwork.com/journals/jamao…
English
Sandra P D'Angelo, MD retweetledi
It's ok at #CTOS2024 to drag me to your poster to pitch your science for Clinical Cancer Research, it the most inspiring thing i get to do!!
English
Sandra P D'Angelo, MD retweetledi
The final countdown until #CTOS2024 meeting!
4 days full of great science and networking with #sarcoma experts - researchers, clinicians & patient advocates from around the world!
If you can't join on-site, follow our social media and interact with colleagues using #CTOSTweeTOS
English
Sandra P D'Angelo, MD retweetledi
Phase 2 Study (JAVELIN Merkel 200): Biomarker analyses - avelumab for metastatic Merkel cell carcinoma. bit.ly/4ezM9um
Română